Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dicerna secures $70mm in convertible stock financing

Executive Summary

Dicerna Pharmaceuticals Inc. (RNAi technology platform for hepatic, cardiovascular and infectious diseases) grossed $70mm through the sale of 700k shares of redeemable convertible preferred stock at $100 per share from existing and new investors led by Bain Capital Life Sciences (also adds Board seat) and including investment from EcoR1 Capital, Comorant Asset Management, RA Capital, Domain Associates and Skyline Ventures.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Private Placement

Related Companies